BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 36861439)

  • 1. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
    Li P; Liu Y; Liang Y; Bo J; Gao S; Hu Y; Hu Y; Huang H; Huang X; Jing H; Ke X; Li J; Li Y; Liu Q; Lu P; Mei H; Niu T; Song Y; Song Y; Su L; Tu S; Wang J; Wu D; Wang Z; Xu K; Ying Z; Yang Q; Zhang Y; Shi F; Zhang B; Zhang H; Zhang X; Zhao M; Zhao W; Zhao X; Huang L; Zhu J; Qian W; Han W; Liang A
    Cancer Biol Med; 2023 Mar; 20(2):129-46. PubMed ID: 36861439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
    Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
    Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
    Li J; Wu Z; Zhao N
    Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
    Makita S; Yoshimura K; Tobinai K
    Cancer Sci; 2017 Jun; 108(6):1109-1118. PubMed ID: 28301076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
    Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
    Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
    Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
    BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies.
    Singh H; Srour SA; Milton DR; McCarty J; Dai C; Gaballa MR; Ammari M; Olivares S; Huls H; De Groot E; Marin D; Petropoulos D; Olson AL; Anderlini P; Im JS; Khouri I; Hosing CM; Rezvani K; Champlin RE; Shpall EJ; Cooper LJN; Kebriaei P
    Front Immunol; 2022; 13():1032397. PubMed ID: 36439104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary Report of the Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical Application.
    Erdoğan E; Yalçın K; Hemşinlioğlu C; Sezgin A; Seyis U; Kançağı DD; Taştan C; Yurtsever B; Turan RD; Çakırsoy D; Abanuz S; Sır Karakuş G; Elek M; Bekoz HS; Gemici Aİ; Sargın D; Arat M; Ferhanoğlu B; Pekgüç E; Örnek S; Büyüktaş D; Birgen N; Ratip S; Ovalı E
    Turk J Haematol; 2022 Aug; 39(3):206-210. PubMed ID: 35848614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.
    Yamshon S; Gribbin C; Chen Z; Demetres M; Pasciolla M; Alhomoud M; Martin P; Shore T
    Transplant Cell Ther; 2024 Jan; 30(1):73.e1-73.e12. PubMed ID: 37279856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies.
    Schorr C; Forindez J; Espinoza-Gutarra M; Mehta R; Grover N; Perna F
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of CAR-T cell therapy for patients with relapsed/refractory B cell non-Hodgkin lymphoma.
    Fu S; Hu Y; Huang H
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):167-174. PubMed ID: 36161292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recapitulated Late-Onset Inflammatory Toxicities and Progressive Dysautonomia with Persistence of Central Memory CD4+ Chimeric Antigen Receptor T Cells in a Case of Transformed Follicular Lymphoma: Case Report.
    Nishimoto M; Takakuwa T; Kuno M; Makuuchi Y; Okamura H; Nakashima Y; Koh H; Namba H; Itoh Y; Hino M; Nakamae H
    Acta Haematol; 2023; 146(4):338-342. PubMed ID: 37088083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
    Hunter BD; Rogalski M; Jacobson CA
    Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
    Lee DW; Kochenderfer JN; Stetler-Stevenson M; Cui YK; Delbrook C; Feldman SA; Fry TJ; Orentas R; Sabatino M; Shah NN; Steinberg SM; Stroncek D; Tschernia N; Yuan C; Zhang H; Zhang L; Rosenberg SA; Wayne AS; Mackall CL
    Lancet; 2015 Feb; 385(9967):517-528. PubMed ID: 25319501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy.
    Gong WJ; Qiu Y; Li MH; Chen LY; Li YY; Yu JQ; Kang LQ; Sun AN; Wu DP; Yu L; Xue SL
    Front Immunol; 2022; 13():922212. PubMed ID: 36105799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
    Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
    Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.
    Chou CK; Turtle CJ
    Expert Opin Biol Ther; 2020 Jun; 20(6):653-664. PubMed ID: 32067497
    [No Abstract]   [Full Text] [Related]  

  • 20. Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Kallam A; Vose JM
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):751-757. PubMed ID: 31648957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.